Provided by Tiger Fintech (Singapore) Pte. Ltd.

Seres Therapeutics

9.31
-0.7700-7.64%
Post-market: 9.310.00000.00%19:48 EDT
Volume:83.17K
Turnover:809.01K
Market Cap:81.16M
PE:531.91
High:10.20
Open:10.02
Low:9.25
Close:10.08
Loading ...

Seres Therapeutics Receives Feedback From FDA on Ser-155 Allogeneic Hematopoietic Stem Cell Transplant (Allo-Hsct) Development Approach

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Inc - Expects FDA Response on Ser-155 Study Protocol in Weeks

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Inc - Ser-155 Receives Breakthrough Therapy and Fast Track Designations

THOMSON REUTERS
·
03 Mar

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

GlobeNewswire
·
03 Mar

Seres Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
28 Feb

Sector Update: Health Care Stocks Flat to Lower Premarket Thursday

MT Newswires Live
·
16 Jan

Seres Therapeutics Receives First of 2 Installments Related to VOWST Sale

MT Newswires Live
·
16 Jan

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to Vowst Sale

THOMSON REUTERS
·
16 Jan

Press Release: Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Dow Jones
·
16 Jan

Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended

MT Newswires Live
·
10 Jan

Seres announces new translational biomarker results from SER-155 Phase 1b study

TIPRANKS
·
09 Jan

Seres Therapeutics Inc - Extends Cash Runway Into Q1 2026

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Inc - Ser-155 Shows 77% Relative Risk Reduction in Bloodstream Infections

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Announces New Translational Biomarker Results From Ser-155 Phase 1B Clinical Study and Provides Corporate Updates

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Inc - Ser-155 Shows Significant Decrease in Fecal Albumin and Systemic Inflammation

THOMSON REUTERS
·
09 Jan

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

GlobeNewswire
·
09 Jan

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

Simply Wall St.
·
26 Dec 2024

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

TIPRANKS
·
16 Dec 2024

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

GlobeNewswire
·
16 Dec 2024

Optimistic Buy Rating for Seres Therapeutics: Breakthrough Therapy Designation and Financial Stability Boost Confidence

TIPRANKS
·
10 Dec 2024